<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337919</url>
  </required_header>
  <id_info>
    <org_study_id>UCL/15/0515</org_study_id>
    <secondary_id>CA-209-445</secondary_id>
    <nct_id>NCT03337919</nct_id>
  </id_info>
  <brief_title>ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma</brief_title>
  <acronym>ANIMATE</acronym>
  <official_title>A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1&#xD;
      inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell&#xD;
      transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a&#xD;
      complete metabolic response (CMR) on FDG-PET-CT scan after 2 cycles of first or second line&#xD;
      salvage therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, phase II, multi-centre study of the safety and efficacy of the&#xD;
      programmed cell death protein 1 (PD-1) inhibitor, nivolumab, as second-line or third-line&#xD;
      salvage therapy, and in particular as a bridge to stem cell transplant (SCT) in relapsed/&#xD;
      refractory classical Hodgkin lymphoma patients not achieving a complete metabolic response&#xD;
      (CMR) on fluorodeoxyglucose positron emission tomography (FDG-PET) scan post 2 cycles of&#xD;
      first or second line salvage therapy.&#xD;
&#xD;
      Approximately 120 patients with relapsed/refractory classical Hodgkin lymphoma will be&#xD;
      registered while undergoing first or second line salvage therapy (first line is preferred).&#xD;
&#xD;
      Patients will have a centrally reviewed PET CT scan after 2 cycles of the salvage therapy&#xD;
      they are receiving (or 4 cycles if they are undergoing treatment with brentuximab vedotin).&#xD;
      Those with complete metabolic response (CMR) on PET CT scan (Deauville score 1-3) will not be&#xD;
      eligible for trial treatment. They will be followed up for trial data collection purposes,&#xD;
      and further management will be at their treating clinician's discretion.&#xD;
&#xD;
      Patients achieving less than CMR on central review of FDG-PET (Deauville score 4-5) will be&#xD;
      eligible to receive up to 8 x 2-weekly nivolumab infusions. 30 patients will be treated on&#xD;
      the trial.&#xD;
&#xD;
      After 4 courses of nivolumab, patients will have an additional centrally reviewed PET-CT scan&#xD;
      (PET4). Patients achieving CMR will stop trial treatment, and enter follow up. Further&#xD;
      treatment will be at their clinician's discretion but is likely to be stem cell transplant&#xD;
      (SCT).Patients with partial metabolic response (PMR) or stable disease (SD) on PET4 will&#xD;
      receive a further 4 cycles of nivolumab, again followed by a centrally reviewed PET-CT scan&#xD;
      (PET8) to assess final response.&#xD;
&#xD;
      Further management after PET8 will be at the discretion of the treating clinician, although&#xD;
      it is anticipated that those with CMR or PMR will proceed to SCT. If PET8 shows less than CMR&#xD;
      (i.e. PMR or SD), patients who consent will have a further biopsy to exclude false positive&#xD;
      PET signal; this will be centrally reviewed.&#xD;
&#xD;
      Patients with progressive metabolic disease (PMD) on nivolumab at any point will stop trial&#xD;
      treatment. If a repeat biopsy is obtained to confirm progressive disease histologically, the&#xD;
      biopsy material will be centrally reviewed.&#xD;
&#xD;
      Patients will be followed up for a minimum of 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm, phase II, multi-centre study. It will use an Ahern single stage design with independent trials steering committee review to monitor for safety and efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) by PET-CT scan following 4-8 cycles of nivolumab</measure>
    <time_frame>4 months</time_frame>
    <description>Rate of patients achieving complete metabolic response (CMR) on PET-CT scan following 4 or 8 cycles of nivolumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival at 1 year; also to be analysed stratified by partial metabolic response vs complete metabolic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival at 1 year; also to be analysed stratified by partial metabolic response (PMR) vs complete metabolic response (CMR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients progressing to stem cell transplant</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patients progressing to autologous or allogeneic stem cell transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events [Safety and toxicity of nivolumab]</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events and serious adverse events occurring in patients treated with nivolumab, in particular autoimmune toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients treated with nivolumab that subsequently die of transplant-related causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related morbidity</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients treated with nivolumab that go on to suffer serious complications of allogeneic transplant (grade 3-4 graft-versus-host disease, hyperacute graft-versus-host disease and steroid-responsive febrile syndrome)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biopsy-negative PMR rate</measure>
    <time_frame>4 months</time_frame>
    <description>Correlation of PET positive disease with histological evidence of disease on post-treatment repeat biopsy to establish biopsy negative PMR rate (subject to patient consent)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serological biomarkers of response to nivolumab</measure>
    <time_frame>5 months</time_frame>
    <description>Correlation of disease response with serological markers such as serum Thymus and activation-regulated chemokine (TARC) levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunological biomarkers of response to treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluate the correlation between response to nivolumab and biological parameters e.g. PD-L1 expression on Reed Sternberg cells</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Up to 8 cycles of nivolumab</description>
    <arm_group_label>Nivolumab</arm_group_label>
    <other_name>OpdivoÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for study registration:&#xD;
&#xD;
          1. Age 16 or over&#xD;
&#xD;
          2. Primary refractory classical Hodgkin lymphoma or classical Hodgkin lymphoma in first&#xD;
             relapse&#xD;
&#xD;
          3. About to receive, or within 14 days of receiving first 2 cycles of first or second&#xD;
             line salvage therapy (4 cycles if receiving treatment with brentuximab vedotin)&#xD;
&#xD;
          4. Fit for autologous stem cell transplantation&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
          6. Willing to comply with the contraceptive requirements of the trial&#xD;
&#xD;
        Exclusion criteria for study registration:&#xD;
&#xD;
          1. Nodular lymphocyte predominant Hodgkin lymphoma&#xD;
&#xD;
          2. Women who are pregnant or breastfeeding&#xD;
&#xD;
          3. History of colitis, inflammatory bowel disease or pneumonitis&#xD;
&#xD;
          4. Patients with autoimmune disorders, except patients with vitiligo, diabetes mellitus&#xD;
             type 1, hypo- and hyperthyroidism not requiring immunosuppressive therapy&#xD;
&#xD;
          5. Known history of hepatitis B or C infection&#xD;
&#xD;
          6. Known HIV infection&#xD;
&#xD;
          7. History of allergy (including severe/life threatening skin reaction) to monoclonal&#xD;
             antibodies, anaphylaxis or uncontrolled allergy&#xD;
&#xD;
          8. Major surgery within 4 weeks prior to registration&#xD;
&#xD;
          9. Myocardial infarction, unstable angina, coronary artery bypass graft, cerebrovascular&#xD;
             accident or transient ischaemic attack within the past 6 months&#xD;
&#xD;
         10. Non-haematological malignancy within the past 3 years (with some exceptions - listed&#xD;
             in protocol)&#xD;
&#xD;
        Inclusion criteria for trial treatment:&#xD;
&#xD;
          1. Has received 2 cycles of first or second line salvage chemotherapy, (4 cycles if&#xD;
             receiving treatment with brentuximab vedotin)&#xD;
&#xD;
          2. PET positive (Deauville score 4 or 5) after 2 cycles of first or second line salvage&#xD;
             chemotherapy (4 cycles if receiving treatment with brentuximab vedotin)&#xD;
&#xD;
          3. Fit for further salvage chemotherapy&#xD;
&#xD;
          4. ECOG performance status 0-1&#xD;
&#xD;
          5. Creatinine clearance &gt;30ml/min calculated by Cockcroft-Gault formula&#xD;
&#xD;
          6. Bilirubin &lt;1.5 x ULN, ALT/AST &lt;2.5 x ULN&#xD;
&#xD;
          7. Adequate bone marrow function (Hb &gt;80g/l, Platelets &gt;50 x 10^9/l, neutrophils &gt;1.0 x&#xD;
             10^9/l)&#xD;
&#xD;
        Exclusion criteria for trial treatment:&#xD;
&#xD;
          1. Deauville score 1-3 after 2 cycles of first or second line salvage chemotherapy (4&#xD;
             cycles if receiving treatment with brentuximab vedotin)&#xD;
&#xD;
          2. Positive serology for hepatitis B or C (unless due to vaccination)&#xD;
&#xD;
          3. Active infection requiring systemic therapy&#xD;
&#xD;
          4. Ongoing requirement for immunosuppressive therapy, apart from inhaled, intranasal,&#xD;
             topical corticosteroids or systemic corticosteroids at low doses (â¤10mg prednisolone&#xD;
             per day, or the equivalent)&#xD;
&#xD;
          5. Chemo- or radiotherapy or corticosteroids at a dose of more than 10mg per day&#xD;
             prednisolone or equivalent within 14 days prior to response PET-CT. NOTE:&#xD;
             corticosteroids can be used AFTER a positive PET-CT scan for symptomatic disease but&#xD;
             must be weaned to a dose of prednisolone â¤10mg/day or less (or equivalent) at least 7&#xD;
             days prior to starting nivolumab.&#xD;
&#xD;
          6. Treatment with any investigational agent within 28 days prior to planned start of&#xD;
             nivolumab&#xD;
&#xD;
          7. Ongoing grade 2-4 non-haematological toxicities related to prior Hodgkin lymphoma&#xD;
             treatments, with the exception of alopecia and grade 2 fatigue&#xD;
&#xD;
          8. Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham Collins</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Lawrie</last_name>
    <phone>+44 (0)20 7679 9860</phone>
    <email>ctc.animate@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tesha Suddason</last_name>
    <phone>+44 (0)20 7679 9860</phone>
    <email>ctc.animate@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Beech</last_name>
      <email>darren.beech@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Bryson Pottinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norfolk &amp; Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Licence</last_name>
      <email>victoria.licence@nnuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nimish Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasheeq Syed</last_name>
      <email>Rasheeq.Syed2@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Pam McKay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahima Ibrahim</last_name>
      <email>rahima.ibrahim@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Fiona Miall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gullberg</last_name>
      <email>martina.gullberg1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rifca Le Dieu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thompson Olaoni</last_name>
      <email>Thompson.Olaoni@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Fields</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Chackathayil</last_name>
      <email>julia.chackathayil@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ruth Pettengell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Gallagher</last_name>
      <email>chelsea.gallagher@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Cunningham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Magallano</last_name>
      <email>Cecilia.Magallano@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Graham Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

